Rocket Pharmaceuticals, Inc. (RCKT)
After hours:
Chart Events
Performance Outlook
| Previous Close | 22.39 |
| Open | 22.29 |
| Bid | 22.44 x 800 |
| Ask | 22.45 x 900 |
| Day's Range | 21.54 - 22.73 |
| 52 Week Range | 7.57 - 23.48 |
| Volume | |
| Avg. Volume | 918,167 |
| Market Cap | 1.75B |
| Beta (5Y Monthly) | 1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.69 |
| Earnings Date | Feb 22, 2023 - Feb 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 51.77 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for RCKT
Related Research
- Rocket Pharmaceuticals, Inc.Daily – Vickers Top Buyers & Sellers for 02/09/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast yearArgus Research
- Insider Monkey
12 Cash-Rich Small Cap Stocks To Invest In
In this article, we will take a look at the 12 cash-rich small cap stocks to invest in. To see more such companies, go directly to 5 Cash-Rich Small Cap Stocks To Invest In. In 2022, standard diversified portfolios suffered through their worst-performing year in a century. Despite the decline in markets this past year, […]
- Zacks
Rocket Pharmaceuticals (RCKT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Rocket Pharmaceuticals (RCKT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- Zacks
Wall Street Analysts Think Rocket Pharmaceuticals (RCKT) Could Surge 163.35%: Read This Before Placing a Bet
The mean of analysts' price targets for Rocket Pharmaceuticals (RCKT) points to a 163.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
